North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

More tepid economic news and a pledge by Donald Trump to push through tariffs on top trading partners stressed Wall Street ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

Police are holding two more suspects over the murder of a Scottish businessman in Kenya. Campbell Scott's body was found tied up in a sack of pineapples in a forest 60 miles (96.5km) from Nairobi, ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

A rebound in stocks sputtered as data showed US manufacturing approached stagnation amid a jump in prices. The S&P 500 erased gains, with a slide in megacaps like Nvidia Corp. and Microsoft Corp. also ...

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.